drugset
drugset / Trial / NCT00205465

Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

NCT00205465 ↗

Phase 2 Completed 64 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis treated for 28 days.

Timeline

Start
2004-12
Primary completion
—
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Belnacasan Small molecule — —

Indications

psoriasis